Moomoo AI 已提取核心訊息
On February 15, 2024, Compugen Ltd., a clinical-stage cancer immunotherapy company, announced the appointment of Michelle Mahler, M.D., as its new Chief Medical Officer, effective March 1, 2024. Dr. Mahler, who joined Compugen in October 2023 as Vice President of Clinical Development, will be taking over from Henry Adewoye, M.D., who is departing the company to pursue other opportunities. Dr. Mahler brings extensive experience from her previous roles at various biotech and pharmaceutical companies, including 1 E therapeutics Ltd. and Aummune Therapeutics Ltd. She has been instrumental in preparing for the COM503 Phase 1 study in partnership with Gilead Sciences and has played a key role in ongoing triple combination studies. Compugen's CEO, Anat Cohen-Dayag, Ph.D., expressed gratitude to Dr. Adewoye for his contributions to the company's transition into a clinical stage and for advancing its clinical and regulatory strategy. Compugen is known for its computational target discovery and is developing a range of cancer immunotherapies, including COM701 and COM902, and has a partnered program, rilvegostomig, in Phase 3 development with AstraZeneca.
On February 15, 2024, Compugen Ltd., a clinical-stage cancer immunotherapy company, announced the appointment of Michelle Mahler, M.D., as its new Chief Medical Officer, effective March 1, 2024. Dr. Mahler, who joined Compugen in October 2023 as Vice President of Clinical Development, will be taking over from Henry Adewoye, M.D., who is departing the company to pursue other opportunities. Dr. Mahler brings extensive experience from her previous roles at various biotech and pharmaceutical companies, including 1 E therapeutics Ltd. and Aummune Therapeutics Ltd. She has been instrumental in preparing for the COM503 Phase 1 study in partnership with Gilead Sciences and has played a key role in ongoing triple combination studies. Compugen's CEO, Anat Cohen-Dayag, Ph.D., expressed gratitude to Dr. Adewoye for his contributions to the company's transition into a clinical stage and for advancing its clinical and regulatory strategy. Compugen is known for its computational target discovery and is developing a range of cancer immunotherapies, including COM701 and COM902, and has a partnered program, rilvegostomig, in Phase 3 development with AstraZeneca.
2024年2月15日，臨床階段的癌症免疫療法公司Compugen有限公司宣佈任命醫學博士米歇爾·馬勒爲新任首席醫學官，自2024年3月1日起生效。馬勒博士於2023年10月加入Compugen擔任臨床開發副總裁，他將接替即將離開公司尋求其他機會的醫學博士亨利·阿德沃耶。馬勒博士曾在包括1 E therapeutics Ltd.和Aummune Therapeutics Ltd在內的多家生物技術和製藥公司任職，積累了豐富的經驗。她在準備與吉利德科學合作進行的 COM503 1期研究中發揮了重要作用，並在正在進行的三聯研究中發揮了關鍵作用。Compugen首席執行官阿納特·科恩-達亞格博士對阿德沃伊博士爲公司過渡到臨床階段以及推進其臨床和監管戰略所做的貢獻表示感謝。Compugen以其計算靶標的發現而聞名，正在開發一系列癌症免疫療法，包括 COM701 和 COM902，並與阿斯利康合作開發了名爲rilvegostomig的第三階段項目。
2024年2月15日，臨床階段的癌症免疫療法公司Compugen有限公司宣佈任命醫學博士米歇爾·馬勒爲新任首席醫學官，自2024年3月1日起生效。馬勒博士於2023年10月加入Compugen擔任臨床開發副總裁，他將接替即將離開公司尋求其他機會的醫學博士亨利·阿德沃耶。馬勒博士曾在包括1 E therapeutics Ltd.和Aummune Therapeutics Ltd在內的多家生物技術和製藥公司任職，積累了豐富的經驗。她在準備與吉利德科學合作進行的 COM503 1期研究中發揮了重要作用，並在正在進行的三聯研究中發揮了關鍵作用。Compugen首席執行官阿納特·科恩-達亞格博士對阿德沃伊博士爲公司過渡到臨床階段以及推進其臨床和監管戰略所做的貢獻表示感謝。Compugen以其計算靶標的發現而聞名，正在開發一系列癌症免疫療法，包括 COM701 和 COM902，並與阿斯利康合作開發了名爲rilvegostomig的第三階段項目。
有用
沒用